Early immunotherapy is highly effective in IgG1/IgG4 positive IgLON5 disease

Thomas Grüter1 · Volker Behrendt1 · Corinna I. Bien2 · Ralf Gold1 · Ilya Ayzenberg1,3 ©

Received: 24 March 2020 / Revised: 12 May 2020 / Accepted: 14 May 2020 / Published online: 22 May 2020
© The Author(s) 2020

Dear Sirs,

In the pathogenesis of anti-IgLON5 disease, there is evidence for both neurodegenerative and autoimmune mechanisms [1–3]. While strong association to anti-IgLON5-antibodies and distinct HLA haplotypes suggest an active role of inflammatory processes, older age of manifestation, progressive neuronal tauopathy without signs of inflammation, and an association to the MAPT-H1 haplotype, are more typical for neurodegenerative diseases [1]. Data on immunotherapy are contradictory and cannot solve this dilemma. Stabilization as well as no therapy effect with lethal outcome have been reported so far [3]. Improvement under immunotherapy is described in a few cases [3, 4].

Here, we present a patient with an acute to subacute bulbar manifestation of anti-IgLON5 disease, mimicking a myasthenic crisis, and a dramatic recovery under immunotherapy started 1 week after disease onset.

An 82-year-old lady suffered for a few days from dysesthesia in her hands and feet, an unsteady gait, and augmented sweating. The patient suffered from a marked fatigue and two until three sleep attacks per day that occurred in passive situations, lasted for 15 until 20 min and did not interfere with her routine activities. Initial clinical examination revealed moderate weakness in cervical flexion and extension (MS 4/5), severe gait ataxia, pronounced dysphagia, dysarthria, hypophonia, and a minimal right-side ptosis, suspicious of myasthenia gravis. Repetitive nerve stimulation as well as brain and spinal MRI were unremarkable. On the second day of admission, she progressed to aphonia, severe dysphagia, and weakness of the neck muscles (MS 3/5). Fiber optic evaluation of swallowing (FEES) revealed a pronounced hypotonic deglutition with penetration and slight aspiration of viscous liquids (Fig. 1a). Under suspicion of a myasthenic crisis, intravenous immunoglobulins (IVIg, 2 g/kg BW) were initiated.

During the next 3 days, her condition improved dramatically, she was able to walk without any help and the neck weakness normalized. Furthermore, her voice became clear and repeated FEES showed a striking improvement without further penetration or aspiration (Fig. 1b). A broad serological screening revealed positive anti-IgLON5 IgG (in both tissue based and cell based immunofluorescence, IgG 1:2560, IgG1 1:80, IgG2 1:40, IgG4 1:640, IgG3 negative), whereas antibody testing against acetylcholine-receptor, muscle-specific kinase and titin resulted negative. The patient refused to perform a lumbar puncture. The patient carried the HLA haplotype DQB1*05:01, but not DRB1*10:01. Five weeks later, she was nearly symptom-free and IVIg therapy (1 g/kg every 4 until 6 weeks) was continued.

Today, 1 year after the commencement of the symptoms, the patient is asymptomatic and lives alone without a care service. Despite dramatic clinical recovery of the patient, the serum titer of anti-IgLON5 antibodies did not decline at the last follow-up.

Here, we describe for the first time a patient with anti-IgLON5 disease and a complete recovery under early immunotherapy. In particular, two factors appear to be decisive for the therapy success in this case.

Firstly, IVIg was started within 1 week after disease onset. A slowly progressive disease course and late diagnosis usually result in substantial therapy delay [2, 5]. In line with this, previously reported therapy effects were less obvious and some authors doubted if an immunosuppressive treatment would be effective in this disease [1, 2]. However, subacute disease progression has been reported
in a few other cases, probably representing a favorable timepoint for immunotherapy initiation [5–7]. Interestingly, up to 20% of patients have a relative rapid clinical presentation, in less than 4 months.

Secondly, we identified both IgG4 and IgG1 anti-IgLON5 antibodies in our patient. Anti-IgLON5-IgG1 (but not IgG4) cause an irreversible internalization of surface IgLON5 in hippocampal neurons [8]. It can be speculated that this early immune-mediated effect on the IgLON5 clusters induces a further intracellular pathological cascade, making later immunotherapy less effective. If true, IgG subunit analysis could reflect ongoing inflammatory activity and probably even predict the immunotherapy response. In line with this, a case with exclusively IgLON5-IgG1 inflammatory changes in the brain biopsy and MRI and a temporary response to immunotherapy has recently been reported [7].

In conclusion, early immunotherapy can be highly effective in anti-IgLON5 disease, confirming a key pathogenetic role of initial autoimmune mechanisms. Despite clinical heterogeneity, a subacute onset of characteristic symptoms, including sleep attacks and bulbar signs, should increase clinical suspicion. Being safe and non-immunosuppressive, IVIg should be tried in suspicious cases without delay.

Acknowledgements Open Access funding provided by Projekt DEAL. The authors thank Christian G. Bien, MD, Bielefeld and Bad Salzuflen, for critically discussing the manuscript.

Author contributions TG design and conceptualized study; acquisition of data; analyzed the data; drafted the manuscript for intellectual content. VB acquisition of data; revised the manuscript for intellectual content. CIB acquisition of data; interpreted the data; revised the manuscript for intellectual content. IA design and conceptualized study; acquisition of data; analyzed the data; drafted the manuscript for intellectual content.

Availability of data and material The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Compliance with ethical standards

Conflicts of interest Dr. Grüter received travel reimbursement from Sanoﬁ Genzyme and Biogen Idec, none related to this manuscript. Dr. Bien reports no disclosures. Dr. Behrendt reports no disclosures. Prof. Gold serves on scientiﬁc advisory boards for Teva Pharmaceutical Industries Ltd., Biogen Idec, Bayer Schering Pharma, and Novartis; has received speaker honoraria from Biogen Idec, Teva Pharmaceutical Industries Ltd., Bayer Schering Pharma, and Novartis; serves as editor for Therapeutic Advances in Neurological Diseases and on the editorial boards of Experimental Neurology and the Journal of Neuroimmunology; and receives research support from Teva Pharmaceutical Industries Ltd., Biogen Idec, Bayer Schering Pharma, Genzyme, Merck Serono, and Novartis, none related to this manuscript. Dr. Ayzenberg received travel grants from Biogen Idec and Guthy-Jackson Charitable Foundation, served on scientiﬁc advisory boards for Roche and Alexion and received research support from Chugai Pharma and Diamed, none related to this manuscript.

Ethical standards The authors received written consent from participants in this case report prior to their inclusion in the study and have them on file in case they are requested by the editor. The manuscript does not contain clinical or animal studies.

Consent to participate The authors received written consent from participants in this case report prior to their inclusion in the study and have them on file in case they are requested by the editor.

Consent for publication Dr. Ayzenberg has full access to all of the data, and the right to publish any and all data separate and apart from any sponsor. All authors have approved the final submitted version.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made. If material is not included in the article’s Creative Commons licence and your intended use is not
References

1. Sabater L, Gaig C, Gelpi E et al (2014) A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol 13(6):575–586. https://doi.org/10.1016/S1474-4422(14)70051-1

2. Gaig C, Graus F, Compta Y et al (2017) Clinical manifestations of the anti-IgLON5 disease. Neurology 88(18):1736–1743. https://doi.org/10.1212/WNL.000000000003887

3. Honorat JA, Komorowski L, Josephs KA et al (2017) IgLON5 antibody: Neurological accompaniments and outcomes in 20 patients. Neurol Neuroimmunol Neuroinflamm 4(5):e385. https://doi.org/10.1212/NXI.0000000000000385

4. Haitao R, Yingmai Y, Yan H et al (2016) Chorea and Parkinsonism associated with autoantibodies to IgLON5 and responsive to immunotherapy. J Neuroimmunol 300:9–10. https://doi.org/10.1016/j.jneuroim.2016.09.012

5. Gaig C, Compta Y (2019) Neurological profiles beyond the sleep disorder in patients with anti-IgLON5 disease. Curr Opin Neurol 32(3):493–499. https://doi.org/10.1097/WCO.0000000000000677

6. Moreno-Estébanez A, Garcia-Ormaechea M, Tijero B et al (2018) Anti-IgLON5 disease responsive to immunotherapy: a case report with an abnormal MRI. Mov Disord Clin Pract 5(6):653–656. https://doi.org/10.1002/mdc3.12679

7. Montagna M, Amir R, de Volder J et al (2018) IgLON5-associated encephalitis with atypical brain magnetic resonance imaging and cerebrospinal fluid changes. Front Neurol 9:329. https://doi.org/10.3389/fneur.2018.00329

8. Sabater L, Planagumà J, Dalmau J et al (2016) Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome. J Neuroinflamm 13(1):226. https://doi.org/10.1186/s12974-016-0689-1